Faboxim - Used for: Lowering high cholesterol and triglycerides in certain patients. It also increases high-density lipoprotein (HDL, "good") cholesterol levels. It is used along with an appropriate diet. It is used in certain patients to reduce the risk of heart attack, stroke, chest pain caused by angina, or blood vessel blockage. It is also used in certain patients to reduce the risk of hospitalization for congestive heart failure, or the need for medical procedures to open blocked heart blood vessels. It may also be used for other conditions as determined by your doctor.
Faboxim is an HMG-CoA reductase inhibitor, also known as a "statin." It works by reducing the production of certain fatty substances in the body, including cholesterol.
Faboxim is in a group of drugs called HMG CoA reductase inhibitors, or "statins." Faboxim reduces levels of "bad" cholesterol (low-density lipoprotein, or LDL) and triglycerides in the blood, while increasing levels of "good" cholesterol (high-density lipoprotein, or HDL).
Faboxim is used to treat high cholesterol, and to lower the risk of stroke, heart attack, or other heart complications in people with type 2 diabetes, coronary heart disease, or other risk factors.
Faboxim is used in adults and children who are at least 10 years old.
Faboxim may also be used for purposes not listed in this medication guide.
Faboxim is a lipid-lowering drugs of the statin group. An inhibition of HMG-CoA reductase leads to a series of sequential reactions that result in reduced intracellular cholesterol content and it is a compensatory increase in activity of LDL receptors and thus accelerate the catabolism of LDL cholesterol.
The lipid-lowering effect of statins is associated with lower levels of total cholesterol by LDL-C. The reduction in LDL cholesterol is dose-dependent and is not linear, but exponential. The inhibitory effect of Faboxim on HMG-CoA reductase by about 70% determined by the activity of its circulating metabolites.
Statins do not affect the activity of lipoprotein lipase and hepatic, no significant effect on the synthesis and catabolism of free fatty acids, so their effect on triglycerides and again vicariously through their main effects on reducing LDL-C.
In addition to lipid-lowering actions, statins have beneficial effects in endothelial dysfunction (pre-clinical sign of early atherosclerosis) in the vascular wall, the state of atheroma, improves blood rheology, have antioxidant, antiproliferative properties.
Faboxim lowers cholesterol levels in patients with homozygous familial hypercholesterolemia, which is usually not amenable to therapy with lipid-lowering agents.
Faboxim, a selective, competitive HMG-CoA reductase inhibitor, is used to lower serum total and LDL cholesterol, apoB, and triglyceride levels while increasing HDL cholesterol. High LDL-C, low HDL-C and high TG concentrations in the plasma are associated with increased risk of atherosclerosis and cardiovascular disease. The total cholesterol to HDL-C ratio is a strong predictor of coronary artery disease and high ratios are associated with higher risk of disease. Increased levels of HDL-C are associated with lower cardiovascular risk. By decreasing LDL-C and TG and increasing HDL-C, Faboxim reduces the risk of cardiovascular morbidity and mortality. Faboxim has a unique structure, long half-life, and hepatic selectivity, explaining its greater LDL-lowering potency compared to other HMG-CoA reductase inhibitors.
Faboxim helps lower your cholesterol level. Excessive cholesterol in your body can clog up your blood vessels. This can lead to many health problems such as strokes and heart disease, including heart attacks. Faboxim is meant to be taken as part of a complete cholesterol management programme that should include exercise, a healthy diet and lifestyle.
Oral Mixed dyslipidaemia
Adult: Initially, 10 or 20 mg daily, may increase at 4-wkly intervals. May initiate with 40 mg once daily in patients who require >45% reduction in low-density lipoprotein cholesterol. Max dose: 80 mg/day. Oral Nonfamilial hypercholesterolaemia
Adult: Initially, 10 or 20 mg daily, may increase at 4-wkly intervals. May initiate with 40 mg once daily in patients who require >45% reduction in low-density lipoprotein cholesterol. Max dose: 80 mg/day. Oral Heterozygous familial hypercholesterolaemia
Adult: Initially, 10 or 20 mg daily. Usual range depending on response: 10-80 mg daily.
Child: 10-17 yr: Initially, 10 mg daily, adjust dose based on response. Max: 20 mg daily.
Adult: PO Mixed dyslipidaemia; Nonfamilial hypercholesterolaemia ; Heterozygous familial hypercholesterolaemia Inital: 10 or 20 mg once daily, may increase slowly if needed. Max: 80 mg/day.
Reduce the amount of cholesterol in blood. Slow the progression of atherosclerosis (hardening) of the arteries that nourish the heart, causing so-called coronary heart disease (CHD). Reduce the development of new atherosclerosis. It is indicated:As an adjunct to diet to reduce elevated total-C, LDL-C, apo B, and TG levels and to increase HDL-C in patients with primary hypercholesterolemia (heterozygous familial and nonfamilial) and mixed dyslipidemia (Fredrickson Types IIa and IIb);As an adjunct to diet for the treatment of patients with elevated serum TG levels (Fredrickson Type IV);.For the treatment of patients with primary dysbetalipoproteinemia (Fredrickson Type III) who do not respond adequately to diet;.To reduce total-C and LDL-C in patients with homozygous familial hypercholesterolemia as an adjunct to other lipid-lowering treatments (e.g., LDL apheresis) or if such treatments are unavailable;.As an adjunct to diet to reduce total-C, LDL-C, and apo B levels in boys and postmenarchal girls, 10 to 17 years of age, with heterozygous familial hypercholesterolemia if after an adequate trial of diet therapy the following findings are present: a. LDL-C remains ? 190 mg/dL orb. LDL-C remains ? 160 mg/dL and: there is a positive family history of premature cardiovascular disease ortwo or more other CVD risk factors are present in the pediatric patient.